整合生物学期刊网

应用天然产物 ›› 2024, Vol. 14 ›› Issue (6): 48-48.DOI: 10.1007/s13659-024-00472-w

• ORIGINAL ARTICLE •    下一篇

Natural and revolutionary tumor-specific T-cell therapy

Zhi Dai, Xue-Meng Liu, Yun-li Zhao, Li-Xing Zhao, Xiao-Dong Luo   

  1. Yunnan Characteristic Plant Extraction Laboratory, Key Laboratory of Medicinal Chemistry for Natural Resource, Ministry of Education, Yunnan Key Laboratory of Research and Development for Natural Products, School of Pharmacy, School of Chemical Science and Technology, Yunnan University, Kunming 650500, People's Republic of China
  • 收稿日期:2024-08-06 出版日期:2024-12-24 发布日期:2024-12-13
  • 通讯作者: Zhi Dai,E-mail:daizhi@ynu.edu.cn;Xiao-Dong Luo,E-mail:xdluo@ynu.edu.cn
  • 基金资助:
    This work was financially supported by the High-level Talent Promotion and Training Project of Kunming (2022SCP003), the Project of Yunnan Characteristic Plant Screening and R&D Service CXO Platform (2022YKZY001), and the Scientific and Technological Innovation Team of Yunnan Province (202105AE160006).

Natural and revolutionary tumor-specific T-cell therapy

Zhi Dai, Xue-Meng Liu, Yun-li Zhao, Li-Xing Zhao, Xiao-Dong Luo   

  1. Yunnan Characteristic Plant Extraction Laboratory, Key Laboratory of Medicinal Chemistry for Natural Resource, Ministry of Education, Yunnan Key Laboratory of Research and Development for Natural Products, School of Pharmacy, School of Chemical Science and Technology, Yunnan University, Kunming 650500, People's Republic of China
  • Received:2024-08-06 Online:2024-12-24 Published:2024-12-13
  • Contact: Zhi Dai,E-mail:daizhi@ynu.edu.cn;Xiao-Dong Luo,E-mail:xdluo@ynu.edu.cn
  • Supported by:
    This work was financially supported by the High-level Talent Promotion and Training Project of Kunming (2022SCP003), the Project of Yunnan Characteristic Plant Screening and R&D Service CXO Platform (2022YKZY001), and the Scientific and Technological Innovation Team of Yunnan Province (202105AE160006).

摘要: Recently the FDA conducted a risk investigation and labeled the Boxed Warning for all BCMA- and CD19-directed CAR-T cell therapy, so does it mean that the public must take risk of secondary cancer to receive cell therapy? Here, without lentivirus and professional antigen presenting cell application, a novel tumor-specific T-cell therapy was successfully developed only by co-culturing MHC+ cancer cells and Naïve-T cells under the CD28 co-stimulatory signals. These tumor-specific T-cells could be separated through cell size and abundantly produced from peripheral blood, and would spontaneously attack target cells that carrying the same tumor antigen while avoiding others in vitro test. Moreover, it markedly decreased 90% tumor nodules companying with greatly improving overall survival (76 days vs 30 days) after twice infusion back to mice. This work maximally avoided the risks of secondary cancer and non-specific killing, and might open a revolutionary beginning of natural tumor-specific T-cell therapy.

关键词: Natural T-cell therapy, Specific killing, MHC+ tumor, CD28 signal, Without virus, Safety

Abstract: Recently the FDA conducted a risk investigation and labeled the Boxed Warning for all BCMA- and CD19-directed CAR-T cell therapy, so does it mean that the public must take risk of secondary cancer to receive cell therapy? Here, without lentivirus and professional antigen presenting cell application, a novel tumor-specific T-cell therapy was successfully developed only by co-culturing MHC+ cancer cells and Naïve-T cells under the CD28 co-stimulatory signals. These tumor-specific T-cells could be separated through cell size and abundantly produced from peripheral blood, and would spontaneously attack target cells that carrying the same tumor antigen while avoiding others in vitro test. Moreover, it markedly decreased 90% tumor nodules companying with greatly improving overall survival (76 days vs 30 days) after twice infusion back to mice. This work maximally avoided the risks of secondary cancer and non-specific killing, and might open a revolutionary beginning of natural tumor-specific T-cell therapy.

Key words: Natural T-cell therapy, Specific killing, MHC+ tumor, CD28 signal, Without virus, Safety